Inspire Medical Systems (2DR) Stock Forecast & Price Target
2DR Analyst Ratings
Hold
4Buy9Hold2Sell
Based on 15 analysts giving stock ratings to Inspire Medical Systems in the past 3 months
2DR Stock 12 Month Forecast
Average Price Target
EUR 64.12▲(4.26% Upside)Based on 15 Wall Street analysts offering 12 month price targets for Inspire Medical Systems in the last 3 months. The average price target is EUR 64.12 with a high forecast of EUR 86.73 and a low forecast of EUR 40.23. The average price target represents a 4.26% change from the last price of EUR 61.50.
Past 12 Months12 Month ForecastJan2026Oct2026
HighEUR 86.73
AverageEUR 64.12
LowEUR 40.23
Highest Price TargetHighestEUR 86.73Average Price TargetEUR 64.12Lowest Price TargetLowestEUR 40.23
Detailed List of Analyst Forecasts
Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
| Christopher Pasquale | Barclays | EUR 58.12→EUR 55.43 | sell | -9.86%Downside | Reiterated | 11/03/26 | ||
| Brett Fishbin | KeyBanc | ― | hold | ― | Reiterated | 11/03/26 | ||
| David Rescott | Robert W. Baird | EUR 65.27→EUR 68.85 | hold | 11.95%Upside | Reiterated | 11/03/26 | ||
| Adam Maeder | Piper Sandler | EUR 53.65→EUR 62.59 | hold | 1.77%Upside | Reiterated | 11/03/26 | ||
| Robbie Marcus | J.P. Morgan | EUR 53.65→EUR 58.12 | hold | -5.50%Downside | Assigned | 11/03/26 | ||
| Suraj Kalia | Oppenheimer | EUR 76.00 | buy | 23.58%Upside | Reiterated | 11/03/26 | ||
| Jonathan Block | Stifel Nicolaus | EUR 76.00 | buy | 23.58%Upside | Reiterated | 11/03/26 | ||
| Larry Biegelsen | Wells Fargo | EUR 50.07→EUR 61.69 | hold | 0.31%Upside | Reiterated | 11/02/26 | ||
| Kendall Au | RBC Capital | EUR 67.06 | hold | 9.04%Upside | Reiterated | 11/02/26 | ||
| Richard Newitter | Truist Financial | EUR 55.43→EUR 69.74 | hold | 13.40%Upside | Reiterated | 10/14/26 | ||
| Anthony Petrone | Mizuho Securities | EUR 58.12→EUR 67.06 | buy | 9.04%Upside | Assigned | 10/13/26 | ||
 Unknown AnalystNot Ranked | Leerink Partners | EUR 52.75→EUR 59.91 | hold | -2.59%Downside | Reiterated | 10/12/26 | ||
| Keith Hinton | Freedom Capital Markets | EUR 63.48→EUR 86.73 | buy | 41.02%Upside | Reiterated | 09/21/26 | ||
| Travis Steed | Bank of America Securities | EUR 34.87→EUR 40.23 | sell | -34.58%Downside | Reiterated | 08/04/26 | ||
| Daniel Markowitz CFA | Evercore ISI | EUR 35.76→EUR 48.28 | hold | -21.49%Downside | Reiterated | 08/04/26 |
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
| Christopher Pasquale | 11/03/26 | EUR 58.12→EUR 55.43 | sell | -9.86%Downside | Reiterated | Barclays | ||
| Brett Fishbin | 11/03/26 | ― | hold | ― | Reiterated | KeyBanc | ||
| David Rescott | 11/03/26 | EUR 65.27→EUR 68.85 | hold | 11.95%Upside | Reiterated | Robert W. Baird | ||
| Adam Maeder | 11/03/26 | EUR 53.65→EUR 62.59 | hold | 1.77%Upside | Reiterated | Piper Sandler | ||
| Robbie Marcus | 11/03/26 | EUR 53.65→EUR 58.12 | hold | -5.50%Downside | Assigned | J.P. Morgan | ||
| Suraj Kalia | 11/03/26 | EUR 76.00 | buy | 23.58%Upside | Reiterated | Oppenheimer | ||
| Jonathan Block | 11/03/26 | EUR 76.00 | buy | 23.58%Upside | Reiterated | Stifel Nicolaus | ||
| Larry Biegelsen | 11/02/26 | EUR 50.07→EUR 61.69 | hold | 0.31%Upside | Reiterated | Wells Fargo | ||
| Kendall Au | 11/02/26 | EUR 67.06 | hold | 9.04%Upside | Reiterated | RBC Capital | ||
| Richard Newitter | 10/14/26 | EUR 55.43→EUR 69.74 | hold | 13.40%Upside | Reiterated | Truist Financial | ||
| Anthony Petrone | 10/13/26 | EUR 58.12→EUR 67.06 | buy | 9.04%Upside | Assigned | Mizuho Securities | ||
| Unknown AnalystNot Ranked | 10/12/26 | EUR 52.75→EUR 59.91 | hold | -2.59%Downside | Reiterated | Leerink Partners | ||
| Keith Hinton | 09/21/26 | EUR 63.48→EUR 86.73 | buy | 41.02%Upside | Reiterated | Freedom Capital Markets | ||
| Travis Steed | 08/04/26 | EUR 34.87→EUR 40.23 | sell | -34.58%Downside | Reiterated | Bank of America Securities | ||
| Daniel Markowitz CFA | 08/04/26 | EUR 35.76→EUR 48.28 | hold | -21.49%Downside | Reiterated | Evercore ISI |
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Best Analysts Covering Inspire Medical Systems
3 Months
Success Rate13/24 ratings generated profit
54%
Average Return
+3.58%
Copying Jonathan Block's trades and holding each position for 3 Months would result in 54.17% of your transactions generating a profit, with an average return of +3.58% per trade.
1 Year
Success Rate16/24 ratings generated profit
67%
Average Return
+30.84%
Copying Jonathan Block's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +30.84% per trade.
2 Years
Success Rate16/24 ratings generated profit
67%
Average Return
+56.61%
Copying Jonathan Block's trades and holding each position for 2 Years would result in 66.67% of your transactions generating a profit, with an average return of +56.61% per trade.
2DR Analyst Recommendation Trends
| Rating | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 |
| Buy | 4 | 4 | 6 | 7 | 6 |
| Hold | 14 | 12 | 11 | 12 | 10 |
| Sell | 3 | 3 | 3 | 2 | 2 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 21 | 19 | 20 | 21 | 18 |
In the current month, 2DR has received 6 Buy Ratings, 10 Hold Ratings, and 2 Sell Ratings. 2DR average Analyst price target in the past 3 months is 64.12.
2DR Financial Forecast
HighEUR 0.89
ConsensusEUR 0.81
LowEUR 0.65
2DR Earnings Forecast
Next quarter’s earnings estimate for 2DR is EUR 0.81 with a range of EUR 0.65 to EUR 0.89. The previous quarter’s EPS was EUR 0.13. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.
HighEUR 225M
ConsensusEUR 218M
LowEUR 212M
2DR Sales Forecast
Next quarter’s sales forecast for 2DR is EUR 217.79M with a range of EUR 212.00M to EUR 224.96M. The previous quarter’s sales results were EUR 184.81M. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.
2DR Stock Forecast FAQ
What is DE:2DR’s average 12-month price target, according to analysts?
Based on analyst ratings, Inspire Medical Systems’s 12-month average price target is €64.12.
What is DE:2DR’s upside potential, based on the analysts’ average price target?
Inspire Medical Systems has 4.26% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Inspire Medical Systems a Buy, Sell or Hold?
Inspire Medical Systems has a consensus rating of Hold, which is based on 4 buy ratings, 9 hold ratings and 2 sell ratings.
What is Inspire Medical Systems’s share price target?
The average share price target for Inspire Medical Systems is €64.12. This is based on 15 Wall Street analysts’ 12-month price targets, issued in the past 3 months. The highest analyst share price target is €86.73, and the lowest forecast is €40.23. The average share price target represents a 4.26% increase from the current price of €61.5.
What do analysts say about Inspire Medical Systems?
Inspire Medical Systems’s analyst rating consensus is a Hold. This is based on the ratings of 15 Wall Street analysts.
How can I buy shares of Inspire Medical Systems?
To buy shares of DE:2DR, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
